Part 2 of Kelvin Stott’s great work on pharma declining R&D ROI. Why aren’t we finding and drugging new therapeutic targets more efficiently?
Part one of a very insightful analysis by Kelvin Stott showing Pharmaceutical IRR will hit 0% by 2020. Why isn’t translational success rising given better research methodologies and richer datasets?
In part two of this series, we demonstrated that knowledge products derive their value by possessing unique insights about a therapeutic target, disease or new molecular entity. Great information architecture is a fundamental building block that enables a company to engineer its insight production process and accelerate the creation of...